Pandemic and Avian Influenza A Viruses in Humans: Epidemiology, Virology, Clinical Characteristics, and Treatment Strategy

Clinics in Chest Medicine

Volumn 38, Issue 1, 2017, Pages 59-70

  Li, Hui ^a   Cao, Bin ^a,b  

^a CAPITAL MEDICAL UNIVERSITY   (China)

^b CHINA JAPAN FRIENDSHIP HOSPITAL   (China)

Author keywords

Avian influenza A viruses; Clinical characteristics; Epidemiology; Pandemic influenza virus; Treatment; Virology

Indexed keywords

AMANTADINE; ANTIOXIDANT; ANTIVIRUS AGENT; AZITHROMYCIN; CLARITHROMYCIN; CORTICOSTEROID; DAS 181; FAVIPIRAVIR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LANINAMIVIR; MACROLIDE; NITAZOXANIDE; OSELTAMIVIR; PERAMIVIR; PROTECTIN D1; RAPAMYCIN; RIBAVIRIN; RIMANTADINE; UNCLASSIFIED DRUG; ZANAMIVIR; INFLUENZA VACCINE;

2009 H1N1 INFLUENZA; ANTIVIRAL RESISTANCE; AVIAN INFLUENZA VIRUS; BACTERIAL INFECTION; DEATH; DRUG EFFICACY; EPIDEMIC; HUMAN; HYPERGLYCEMIA; IMMUNOMODULATION; INCIDENCE; INFECTION RISK; INFLUENZA A; INFLUENZA A (H1N1); INFLUENZA A (H5N1); INFLUENZA A (H7N9); INFLUENZA A VIRUS (H1N1); INFLUENZA A VIRUS (H5N1); INFLUENZA A VIRUS (H7N9); MORBIDITY; MORTALITY; MYCOSIS; NONHUMAN; PANDEMIC INFLUENZA; PATHOGENESIS; PNEUMONIA; REVIEW; RISK FACTOR; SIDE EFFECT; VIRUS SHEDDING; INFLUENZA, HUMAN; VIROLOGY;

DISEASE OUTBREAKS; HUMANS; INFLUENZA VACCINES; INFLUENZA, HUMAN;

EID: 85008197475     PISSN: 02725231     EISSN: 15578216     Source Type: Journal    
DOI: 10.1016/j.ccm.2016.11.005     Document Type: Review

References (97)

1. 1 Dawood, F.S., Iuliano, A.D., Reed, C., et al. Estimated global mortality associated with the first 12 months of 2009 pandemic influenza A H1N1 virus circulation: a modelling study. Lancet Infect Dis 12 (2012), 687–695.
2. 2 Neumann, G., Kawaoka, Y., Transmission of influenza A viruses. Virology 479–80 (2015), 234–246.
3. 3 WHO. FluNet summary. Available at: http://www.who.int/influenza/gisrs_laboratory/updates/summaryreport/en/. Accessed February 21, 2016.
4. 4 Kurtz, J., Manvell, R.J., Banks, J., Avian influenza virus isolated from a woman with conjunctivitis. Lancet 348 (1996), 901–902.
5. 5 Chan, P.K., Outbreak of avian influenza A(H5N1) virus infection in Hong Kong in 1997. Clin Infect Dis 34:Suppl 2 (2002), S58–S64.
6. 6 Peiris, M., Yuen, K.Y., Leung, C.W., et al. Human infection with influenza H9N2. Lancet 354 (1999), 916–917.
7. 7 Abdelwhab, E.M., Veits, J., Mettenleiter, T.C., Prevalence and control of H7 avian influenza viruses in birds and humans. Epidemiol Infect 142 (2014), 896–920.
8. 8 Tweed, S.A., Skowronski, D.M., David, S.T., et al. Human illness from avian influenza H7N3, British Columbia. Emerg Infect Dis 10 (2004), 2196–2199.
9. 9 Arzey, G.G., Kirkland, P.D., Arzey, K.E., et al. Influenza virus A (H10N7) in chickens and poultry abattoir workers, Australia. Emerg Infect Dis 18 (2012), 814–816.
10. 10 Ogata, T., Yamazaki, Y., Okabe, N., et al. Human H5N2 avian influenza infection in Japan and the factors associated with high H5N2-neutralizing antibody titer. J Epidemiol 18 (2008), 160–166.
11. 11 Human infection with pandemic A (H1N1) 2009 influenza virus: clinical observations in hospitalized patients, Americas, July 2009-update. Wkly Epidemiol Rec 84 (2009), 305–308 [in English, French].
12. 12 Centers for Disease Control and Prevention (CDC), Notes from the field: outbreak of influenza A (H3N2) virus among persons and swine at a county fair–Indiana, July 2012. MMWR Morb Mortal Wkly Rep, 61, 2012, 561.
13. 13 Gao, R., Cao, B., Hu, Y., et al. Human infection with a novel avian-origin influenza A (H7N9) virus. N Engl J Med 368 (2013), 1888–1897.
14. 14 Chen, S., Li, Z., Hu, M., et al. Knowledge, attitudes, and practices (KAP) relating to avian influenza (H10N8) among farmers’ markets workers in Nanchang, China. PLoS One, 10, 2015, e0127120.
15. 15 Shi, W., Shi, Y., Wu, Y., et al. Origin and molecular characterization of the human-infecting H6N1 influenza virus in Taiwan. Protein Cell 4 (2013), 846–853.
16. 16 Chen, T., Zhang, R., Symptoms seem to be mild in children infected with avian influenza A (H5N6) and other subtypes. J Infect 71 (2015), 702–703.
17. 17 WHO. Influenza at the human-animal interface. Available at: http://www.who.int/influenza/human animal interface Influenza Summary IRA HA interface. Accessed February 25, 2016.
18. 18 Yuen, K.Y., Chan, P.K., Peiris, M., et al. Clinical features and rapid viral diagnosis of human disease associated with avian influenza A H5N1 virus. Lancet 351 (1998), 467–471.
19. 19 Casado, I., Martinez-Baz, I., Burgui, R., et al. Household transmission of influenza A(H1N1)pdm09 in the pandemic and post-pandemic seasons. PLoS One, 9, 2014, e108485.
20. 20 Qi, X., Qian, Y.H., Bao, C.J., et al. Probable person to person transmission of novel avian influenza A (H7N9) virus in Eastern China, 2013: epidemiological investigation. BMJ, 347, 2013, f4752.
21. 21 Li, Q., Zhou, L., Zhou, M., et al. Epidemiology of human infections with avian influenza A(H7N9) virus in China. N Engl J Med 370 (2014), 520–532.
22. 22 Wang, H., Feng, Z., Shu, Y., et al. Probable limited person-to-person transmission of highly pathogenic avian influenza A (H5N1) virus in China. Lancet 371 (2008), 1427–1434.
23. 23 Ungchusak, K., Auewarakul, P., Dowell, S.F., et al. Probable person-to-person transmission of avian influenza A (H5N1). N Engl J Med 352 (2005), 333–340.
24. 24 Long, J.S., Benfield, C.T., Barclay, W.S., One-way trip: influenza virus’ adaptation to gallinaceous poultry may limit its pandemic potential. Bioessays 37 (2015), 204–212.
25. 25 Muramoto, Y., Noda, T., Kawakami, E., et al. Identification of novel influenza A virus proteins translated from PA mRNA. J Virol 87 (2013), 2455–2462.
26. 26 Shinya, K., Ebina, M., Yamada, S., et al. Avian flu: influenza virus receptors in the human airway. Nature 440 (2006), 435–436.
27. 27 de Graaf, M., Fouchier, R.A., Role of receptor binding specificity in influenza A virus transmission and pathogenesis. EMBO J 33 (2014), 823–841.
28. 28 Noda, T., Kawaoka, Y., Packaging of influenza virus genome: robustness of selection. Proc Natl Acad Sci U S A 109 (2012), 8797–8798.
29. 29 Chou, Y.Y., Vafabakhsh, R., Doganay, S., et al. One influenza virus particle packages eight unique viral RNAs as shown by FISH analysis. Proc Natl Acad Sci U S A 109 (2012), 9101–9106.
30. 30 Tripathi, S., Batra, J., Lal, S.K., Interplay between influenza A virus and host factors: targets for antiviral intervention. J Virol 160 (2015), 1877–1891.
31. 31 Korteweg, C., Gu, J., Pathology, molecular biology, and pathogenesis of avian influenza A (H5N1) infection in humans. Am J Pathol 172 (2008), 1155–1170.
32. 32 Yu, L., Wang, Z., Chen, Y., et al. Clinical, virological, and histopathological manifestations of fatal human infections by avian influenza A(H7N9) virus. Clin Infect Dis 57 (2013), 1449–1457.
33. 33 Shieh, W.J., Blau, D.M., Denison, A.M., et al. 2009 pandemic influenza A (H1N1): pathology and pathogenesis of 100 fatal cases in the United States. Am J Pathol 177 (2010), 166–175.
34. 34 de Jong, M.D., Simmons, C.P., Thanh, T.T., et al. Fatal outcome of human influenza A (H5N1) is associated with high viral load and hypercytokinemia. Nat Med 12 (2006), 1203–1207.
35. 35 Hu, Y., Lu, S., Song, Z., et al. Association between adverse clinical outcome in human disease caused by novel influenza A H7N9 virus and sustained viral shedding and emergence of antiviral resistance. Lancet 381 (2013), 2273–2279.
36. 36 Guo, J., Huang, F., Liu, J., et al. The serum profile of hypercytokinemia factors identified in H7N9-infected patients can predict fatal outcomes. Sci Rep, 5, 2015, 10942.
37. 37 Zhao, Y., Zhang, Y.H., Denney, L., et al. High levels of virus-specific CD4+ T cells predict severe pandemic influenza A virus infection. Am J Respir Crit Care Med 186 (2012), 1292–1297.
38. 38 Mohn, K.G., Cox, R.J., Tunheim, G., et al. Immune responses in acute and convalescent patients with mild, moderate and severe disease during the 2009 influenza pandemic in Norway. PLoS One, 10, 2015, e0143281.
39. 39 Pulendran, B., Maddur, M.S., Innate immune sensing and response to influenza. Curr Top Microbiol Immunol 386 (2015), 23–71.
40. 40 Tsai, S.Y., Segovia, J.A., Chang, T.H., et al. DAMP molecule S100A9 acts as a molecular pattern to enhance inflammation during influenza A virus infection: role of DDX21-TRIF-TLR4-MyD88 pathway. PLoS Pathog, 10, 2014, e1003848.
41. 41 Duan, S., Thomas, P.G., Balancing immune protection and immune pathology by CD8(+) T-cell responses to influenza infection. Front Immunol, 7, 2016, 25.
42. 42 Meliopoulos, V.A., Karlsson, E.A., Kercher, L., et al. Human H7N9 and H5N1 influenza viruses differ in induction of cytokines and tissue tropism. J Virol 88 (2014), 12982–12991.
43. 43 Leung, Y.H., Nicholls, J.M., Ho, C.K., et al. Highly pathogenic avian influenza A H5N1 and pandemic H1N1 virus infections have different phenotypes in Toll-like receptor 3 knockout mice. J Gen Virol 95 (2014), 1870–1879.
44. 44 Mata-Marin, L.A., Mata-Marin, J.A., Vasquez-Mota, V.C., et al. Risk factors associated with mortality in patients infected with influenza A/H1N1 in Mexico. BMC Res Notes, 8, 2015, 432.
45. 45 Ergonul, O., Alan, S., Ak, O., et al. Predictors of fatality in pandemic influenza A (H1N1) virus infection among adults. BMC Infect Dis, 14, 2014, 317.
46. 46 Muthuri, S.G., Venkatesan, S., Myles, P.R., et al. Effectiveness of neuraminidase inhibitors in reducing mortality in patients admitted to hospital with influenza A H1N1pdm09 virus infection: a meta-analysis of individual participant data. Lancet Respir Med 2 (2014), 395–404.
47. 47 Wang, C., Yu, H., Horby, P.W., et al. Comparison of patients hospitalized with influenza A subtypes H7N9, H5N1, and 2009 pandemic H1N1. Clin Infect Dis 58 (2014), 1095–1103.
48. 48 Meijer, W.J., van Noortwijk, A.G., Bruinse, H.W., et al. Influenza virus infection in pregnancy: a review. Acta Obstet Gynecol Scand 94 (2015), 797–819.
49. 49 Ren, Y.Y., Yin, Y.Y., Li, W.Q., et al. Risk factors associated with severe manifestations of 2009 pandemic influenza A (H1N1) infection in China: a case-control study. Virol J, 10, 2013, 149.
50. 50 Ji, H., Gu, Q., Chen, L.L., et al. Epidemiological and clinical characteristics and risk factors for death of patients with avian influenza A H7N9 virus infection from Jiangsu Province, Eastern China. PLoS One, 9, 2014, e89581.
51. 51 Ip, D.K., Liao, Q., Wu, P., et al. Detection of mild to moderate influenza A/H7N9 infection by China's national sentinel surveillance system for influenza-like illness: case series. BMJ, 346, 2013, f3693.
52. 52 Gao, H.N., Lu, H.Z., Cao, B., et al. Clinical findings in 111 cases of influenza A (H7N9) virus infection. N Engl J Med 368 (2013), 2277–2285.
53. 53 Pfister, R., Kochanek, M., Leygeber, T., et al. Procalcitonin for diagnosis of bacterial pneumonia in critically ill patients during 2009 H1N1 influenza pandemic: a prospective cohort study, systematic review and individual patient data meta-analysis. Crit Care, 18, 2014, R44.
54. 54 Rodriguez, A.H., Aviles-Jurado, F.X., Diaz, E., et al. Procalcitonin (PCT) levels for ruling-out bacterial coinfection in ICU patients with influenza: A CHAID decision-tree analysis. J Infect 72 (2016), 143–151.
55. 55 Qureshi, N.R., Hien, T.T., Farrar, J., et al. The radiologic manifestations of H5N1 avian influenza. J Thorac Imaging 21 (2006), 259–264.
56. 56 Wang, Q., Zhang, Z., Shi, Y., et al. Emerging H7N9 influenza A (novel reassortant avian-origin) pneumonia: radiologic findings. Radiology 268 (2013), 882–889.
57. 57 Bakhshayeshkaram, M., Saidi, B., Tabarsi, P., et al. Imaging Findings in Patients With H1N1 Influenza A Infection. Iran J Radiol 8 (2011), 230–234.
58. 58 Dugas, A.F., Valsamakis, A., Atreya, M.R., et al. Clinical diagnosis of influenza in the ED. Am J Emerg Med 33 (2015), 770–775.
59. 59 Gharabaghi, F., Hawan, A., Drews, S.J., et al. Evaluation of multiple commercial molecular and conventional diagnostic assays for the detection of respiratory viruses in children. Clin Microbiol Infect 17 (2011), 1900–1906.
60. 60 Zumla, A., Memish, Z.A., Maeurer, M., et al. Emerging novel and antimicrobial-resistant respiratory tract infections: new drug development and therapeutic options. Lancet Infect Dis 14 (2014), 1136–1149.
61. 61 Morita, M., Kuba, K., Ichikawa, A., et al. The lipid mediator protectin D1 inhibits influenza virus replication and improves severe influenza. Cell 153 (2013), 112–125.
62. 62 Tam, V.C., Quehenberger, O., Oshansky, C.M., et al. Lipidomic profiling of influenza infection identifies mediators that induce and resolve inflammation. Cell 154 (2013), 213–227.
63. 63 Paterson, J.C., Miller, M.H., Dillon, J.F., Update on the treatment of hepatitis C genotypes 2-6. Curr Opin Infect Dis 27 (2014), 540–544.
64. 64 Kim, W.Y., Young Suh, G., Huh, J.W., et al. Triple-combination antiviral drug for pandemic H1N1 influenza virus infection in critically ill patients on mechanical ventilation. Antimicrob Agents Chemother 55 (2011), 5703–5709.
65. 65 Seo, S., Englund, J.A., Nguyen, J.T., et al. Combination therapy with amantadine, oseltamivir and ribavirin for influenza A infection: safety and pharmacokinetics. Antivir Ther 18 (2013), 377–386.
66. 66 Hurt, A.C., The epidemiology and spread of drug resistant human influenza viruses. Curr Opin Virol 8 (2014), 22–29.
67. 67 Chen, Y., Liang, W., Yang, S., et al. Human infections with the emerging avian influenza A H7N9 virus from wet market poultry: clinical analysis and characterisation of viral genome. Lancet 381 (2013), 1916–1925.
68. 68 Govorkova, E.A., Baranovich, T., Seiler, P., et al. Antiviral resistance among highly pathogenic influenza A (H5N1) viruses isolated worldwide in 2002-2012 shows need for continued monitoring. Antiviral Res 98 (2013), 297–304.
69. 69 Meijer, A., Rebelo-de-Andrade, H., Correia, V., et al. Global update on the susceptibility of human influenza viruses to neuraminidase inhibitors, 2012-2013. Antiviral Res 110 (2014), 31–41.
70. 70 Takashita, E., Meijer, A., Lackenby, A., et al. Global update on the susceptibility of human influenza viruses to neuraminidase inhibitors, 2013-2014. Antiviral Res 117 (2015), 27–38.
71. 71 Li, C., Yang, P., Zhang, Y., et al. Corticosteroid treatment ameliorates acute lung injury induced by 2009 swine origin influenza A (H1N1) virus in mice. PloS One, 7, 2012, e44110.
72. 72 Ottolini, M., Blanco, J., Porter, D., et al. Combination anti-inflammatory and antiviral therapy of influenza in a cotton rat model. Pediatr Pulmonol 36 (2003), 290–294.
73. 73 Torres, A., Sibila, O., Ferrer, M., et al. Effect of corticosteroids on treatment failure among hospitalized patients with severe community-acquired pneumonia and high inflammatory response: a randomized clinical trial. JAMA 313 (2015), 677–686.
74. 74 Blum, C.A., Nigro, N., Briel, M., et al. Adjunct prednisone therapy for patients with community-acquired pneumonia: a multicentre, double-blind, randomised, placebo-controlled trial. Lancet 385 (2015), 1511–1518.
75. 75 Delaney, J.W., Pinto, R., Long, J., et al. The influence of corticosteroid treatment on the outcome of influenza A(H1N1pdm09)-related critical illness. Crit Care, 20, 2016, 75.
76. 76 Laidler, M.R., Thomas, A., Baumbach, J., et al. Statin treatment and mortality: propensity score-matched analyses of 2007-2008 and 2009-2010 laboratory-confirmed influenza hospitalizations. Open Forum Infect Dis, 2, 2015, ofv028.
77. 77 Ishii, H., Komiya, K., Yamagata, E., et al. Clarithromycin has limited effects in non-elderly, non-severe patients with seasonal influenza virus A infection. J Infect 64 (2012), 343–345.
78. 78 Kakeya, H., Seki, M., Izumikawa, K., et al. Efficacy of combination therapy with oseltamivir phosphate and azithromycin for influenza: a multicenter, open-label, randomized study. PLoS One, 9, 2014, e91293.
79. 79 Martin-Loeches, I., Bermejo-Martin, J.F., Valles, J., et al. Macrolide-based regimens in absence of bacterial co-infection in critically ill H1N1 patients with primary viral pneumonia. Intensive Care Med 39 (2013), 693–702.
80. 80 Wang, C.H., Chung, F.T., Lin, S.M., et al. Adjuvant treatment with a mammalian target of rapamycin inhibitor, sirolimus, and steroids improves outcomes in patients with severe H1N1 pneumonia and acute respiratory failure. Crit Care Med 42 (2014), 313–321.
81. 81 Lai, K.Y., Ng, W.Y., Osburga Chan, P.K., et al. High-dose N-acetylcysteine therapy for novel H1N1 influenza pneumonia. Ann Intern Med 152 (2010), 687–688.
82. 82 Linko, R., Pettila, V., Ruokonen, E., et al. Corticosteroid therapy in intensive care unit patients with PCR-confirmed influenza A(H1N1) infection in Finland. Acta Anaesthesiol Scand 55 (2011), 971–979.
83. 83 Lee, N., Leo, Y.S., Cao, B., et al. Neuraminidase inhibitors, superinfection and corticosteroids affect survival of influenza patients. Eur Respir J 45 (2015), 1642–1652.
84. 84 Brun-Buisson, C., Richard, J.C., Mercat, A., et al. Early corticosteroids in severe influenza A/H1N1 pneumonia and acute respiratory distress syndrome. Am J Respir Crit Care Med 183 (2011), 1200–1206.
85. 85 Kim, S.H., Hong, S.B., Yun, S.C., et al. Corticosteroid treatment in critically ill patients with pandemic influenza A/H1N1 2009 infection: analytic strategy using propensity scores. Am J Respir Crit Care Med 183 (2011), 1207–1214.
86. 86 Diaz, E., Martin-Loeches, I., Canadell, L., et al. Corticosteroid therapy in patients with primary viral pneumonia due to pandemic (H1N1) 2009 influenza. J Infect 64 (2012), 311–318.
87. 87 Xi, X., Xu, Y., Jiang, L., et al. Hospitalized adult patients with 2009 influenza A(H1N1) in Beijing, China: risk factors for hospital mortality. BMC Infect Dis, 10, 2010, 256.
88. 88 Cao, B., Gao, H., Zhou, B., et al. Adjuvant corticosteroid treatment in adults with influenza A (H7N9) viral pneumonia. Crit Care Med 44:6 (2016), e318–e328.
89. 89 Liem, N.T., Tung, C.V., Hien, N.D., et al. Clinical features of human influenza A (H5N1) infection in Vietnam: 2004-2006. Clin Infect Dis 48 (2009), 1639–1646.
90. 90 Vandermeer, M.L., Thomas, A.R., Kamimoto, L., et al. Association between use of statins and mortality among patients hospitalized with laboratory-confirmed influenza virus infections: a multistate study. J Infect Dis 205 (2012), 13–19.
91. 91 Kwong, J.C., Li, P., Redelmeier, D.A., Influenza morbidity and mortality in elderly patients receiving statins: a cohort study. PLoS One, 4, 2009, e8087.
92. 92 Cao, B., Hayden, F.G., Therapy of H7N9 pneumonia: current perspectives. Expert Rev Anti Infect Ther 11 (2013), 1123–1126.
93. 93 Yang, M., Gao, H., Chen, J., et al. Bacterial coinfection is associated with severity of avian influenza A (H7N9), and procalcitonin is a useful marker for early diagnosis. Diagn Microbiol Infect Dis 84 (2016), 165–169.
94. 94 Brundage, J.F., Interactions between influenza and bacterial respiratory pathogens: implications for pandemic preparedness. Lancet Infect Dis 6 (2006), 303–312.
95. 95 Martin-Loeches, I., Sanchez-Corral, A., Diaz, E., et al. Community-acquired respiratory coinfection in critically ill patients with pandemic 2009 influenza A(H1N1) virus. Chest 139 (2011), 555–562.
96. 96 Chertow, D.S., Memoli, M.J., Bacterial coinfection in influenza: a grand rounds review. JAMA 309 (2013), 275–282.
97. 97 Estenssoro, E., Rios, F.G., Apezteguia, C., et al. Pandemic 2009 influenza A in Argentina: a study of 337 patients on mechanical ventilation. Am J Respir Crit Care Med 182 (2010), 41–48.